| Literature DB >> 21652069 |
Sharmilan Thanendrarajan1, Michael Nowak, Hinrich Abken, Ingo G H Schmidt-Wolf.
Abstract
The immune system can be harnessed to fight cancer by active (stimulating the patient's intrinsic immune response to cancer) and by passive (transfer of active humoral or cellular immunity) immunotherapy. While for each strategy proof-of-principle was provided, clinical benefit was limited likely due to malfunction of lymphocytes. Increasing knowledge of both the mechanism of vaccination through dendritic cells (DCs) and the potency of a subset of natural killer T lymphocytes termed cytokine-induced killer (CIK) cells led to new strategies through combining adoptive and passive immunotherapy. This review summarizes most recent clinical trials indicating that CIK cells can substantially enhance the effect of tumor vaccines and discusses the potential therapeutic benefit in the long-term control of tumor progression.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21652069 DOI： 10.1016/j.leukres.2011.05.005
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156